LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Corcept Therapeutics Inc

Gesloten

SectorGezondheidszorg

72.94 -1.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

71.56

Max

73.13

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

35M

Verkoop

37M

194M

K/W

Sectorgemiddelde

63.598

35.664

EPS

0.169

Winstmarge

18.078

Werknemers

500

EBITDA

23M

27M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+81.96% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

173M

7.5B

Vorige openingsprijs

74.84

Vorige sluitingsprijs

72.94

Nieuwssentiment

By Acuity

42%

58%

158 / 371 Rangschikking in Healthcare

Corcept Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2025, 22:41 UTC

Belangrijke Marktbewegers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sep 2025, 16:04 UTC

Belangrijke Marktbewegers

Upexi Shares Climb on Solana Gains

12 sep 2025, 15:03 UTC

Belangrijke Marktbewegers

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 20:09 UTC

Winsten

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:16 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:03 UTC

Marktinformatie

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sep 2025, 18:59 UTC

Marktinformatie

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sep 2025, 18:38 UTC

Marktinformatie
Winsten

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sep 2025, 18:33 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sep 2025, 18:22 UTC

Marktinformatie

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sep 2025, 16:56 UTC

Marktinformatie

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sep 2025, 16:22 UTC

Winsten

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 16:19 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

12 sep 2025, 16:11 UTC

Winsten

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sep 2025, 15:37 UTC

Marktinformatie

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sep 2025, 15:22 UTC

Marktinformatie

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sep 2025, 15:07 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 14:34 UTC

Marktinformatie

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sep 2025, 14:10 UTC

Marktinformatie

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sep 2025, 13:58 UTC

Marktinformatie

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sep 2025, 13:58 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 13:57 UTC

Winsten

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sep 2025, 13:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 sep 2025, 13:56 UTC

Marktinformatie

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sep 2025, 13:54 UTC

Marktinformatie

U.S. Natural Gas Recovers Ground -- Market Talk

Peer Vergelijking

Prijswijziging

Corcept Therapeutics Inc Prognose

Koersdoel

By TipRanks

81.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 135.25 USD  81.96%

Hoogste 145 USD

Laagste 121 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corcept Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Sentiment

By Acuity

158 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat